Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-12-16

Clinical Trial Update: A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. [Phase 1, Phase 2]

View source ↗

Summary

APG-2575 is being studied in Phase 1 and Phase 2 trials for mild-to-moderate systemic lupus erythematosus, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: SLE | Phase 1, Phase 2 | Status: RECRUITING